Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 756 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... June 27, 2022 Tomorrow is National Prescription Drug Take-Back Day! April 29, 2022 EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide August 10, 2020 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... May 26, 2022 Load more HOT NEWS Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... Personalised blood test could help predict which lung cancers might return FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them
